This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety of Thoracoscopy in Patients With High Risk

This study has been completed.
Information provided by (Responsible Party):
Muzaffer Metintas, Eskisehir Osmangazi University Identifier:
First received: August 26, 2010
Last updated: September 24, 2012
Last verified: September 2012
Medical thoracoscopy can be performed for diagnostic as well as therapeutic purposes. Thoracoscopy in the diagnosis of pleural diseases is highly sensitive for detecting pleural neoplasia with negative pleural fluid cytology and in the diagnosis of tuberculosis. The indication of thoracoscopy in patients with pleural effusion has been optimized. In some studies medical thoracoscopy has been claimed a useful diagnostic tool with a very low rate of complications. However the investigators do not know its safety on high risk patients. Because many patients having suspected malignancy have bed conditions due to other health problems such as coronary heart diseases, COPD, arrythmia, hypoxemia. In this study the investigators aimed to test the safety of medical thoracoscopy in the patients with high risk for complications.

Pleural Diseases

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Safety of Thoracoscopy in Patients With High Risk

Resource links provided by NLM:

Further study details as provided by Muzaffer Metintas, Eskisehir Osmangazi University:

Primary Outcome Measures:
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 6 years ]
    All participants will have been followed for side effects of medical thoracoscopy. All side effects established in the special forms designed for this study. Side effects measured and recorded according to each characteristic such as pain, air leakege, pneumothorax, empyema, local infection, haemorragy etc.

Enrollment: 355
Study Start Date: January 2002
Study Completion Date: December 2010
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Patients with high risk
Patients in normal conditions


Ages Eligible for Study:   20 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who require thoracoscpic investigation

Inclusion Criteria:

  • Patients with exudative pleural effusion

Exclusion Criteria:

  • Patients without pleural effusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01193439

Eskisehir, Turkey
Sponsors and Collaborators
Eskisehir Osmangazi University
Principal Investigator: Muzaffer Metintas, Professor Head of Department, Professor of pulmonary medicine
  More Information

Responsible Party: Muzaffer Metintas, MD, Eskisehir Osmangazi University Identifier: NCT01193439     History of Changes
Other Study ID Numbers: 082010/1
Study First Received: August 26, 2010
Last Updated: September 24, 2012

Keywords provided by Muzaffer Metintas, Eskisehir Osmangazi University:
pleural diseases

Additional relevant MeSH terms:
Pleural Diseases
Respiratory Tract Diseases processed this record on September 19, 2017